



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/464,685	12/16/99	GLUCKSMANN	M 5800-2B

000826 HM12/0523  
ALSTON & BIRD LLP  
BANK OF AMERICA PLAZA  
101 SOUTH TRYON STREET, SUITE 4000  
CHARLOTTE NC 28280-4000

EXAMINER	
WANG, A	
ART UNIT	PAPER NUMBER
1635	

DATE MAILED: 05/20/21

Below is a communication from the EXAMINER in charge of this application

COMMISSIONER OF PATENTS AND TRADEMARKS

### ADVISORY ACTION

☒ THE PERIOD FOR RESPONSE:

a) ☒ is extended to run \_\_\_\_\_ or continues to run 3 months from the date of the final rejection

b) ☐ expires three months from the date of the final rejection or as of the mailing date of this Advisory Action, whichever is later. In no event however, will the statutory period for the response expire later than six months from the date of the final rejection.

Any extension of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and the appropriate fee. The date on which the response, the petition, and the fee have been filed is the date of the response and also the date for the purposes of determining the period of extension and the corresponding amount of the fee. Any extension fee pursuant to 37 CFR 1.17 will be calculated from the date of the originally set shortened statutory period for response or as set forth in b) above.

☐ Appellant's Brief is due in accordance with 37 CFR 1.192(a).

☒ Applicant's response to the final rejection, filed 4/30/01, has been considered with the following effect, but it is not deemed to place the application in condition for allowance:

1. ☐ The proposed amendments to the claim and/or specification will not be entered and the final rejection stands because:

- ☐ There is no convincing showing under 37 CFR 1.116(b) why the proposed amendment is necessary and was not earlier presented.
- ☐ They raise new issues that would require further consideration and/or search. (See Note).
- ☐ They raise the issue of new matter. (See Note).
- ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal.
- ☐ They present additional claims without cancelling a corresponding number of finally rejected claims.

NOTE: \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

2. ☐ Newly proposed or amended claims \_\_\_\_\_ would be allowed if submitted in a separately filed amendment cancelling the non-allowable claims.

3. ☒ Upon the filing an appeal, the proposed amendment ☐ will be entered ☐ will not be entered and the status of the claims will be as follows:

Claims allowed: none  
Claims objected to: none  
Claims rejected: 73, 74, 81, & 88-96 (reasons of record)

However:

☐ Applicant's response has overcome the following rejection(s): \_\_\_\_\_

ANDREW WANG  
PATENT EXAMINER  
1C 1600

4. ☒ The affidavit, exhibit or request for reconsideration has been considered but does not overcome the rejection because applicant's assertion that the claimed polypeptide is related to blood cell progenitor disorders is unsupported. Figure 7 and page 15 merely state that said protein is expressed in normal cells.

5. ☐ The affidavit or exhibit will not be considered because applicant has not shown good and sufficient reasons why it was not earlier presented.

☐ The proposed drawing correction ☐ has ☐ has not been approved by the examiner.

☒ Other Applicants have not shown any activity for the protein nor any disease states caused by aberrant expression. Further, applicants base their arguments on proteins with known activity for the alleged activity but as was stated in the rejection, applicants have not provided any specific or substantial asserted evidence for the claimed protein. Furthermore, an invention cannot be enabled if there is known ability as is the case.